02005.HK
SSY Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.73
−0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.0B | 4.2B | 5.8B | 6.5B | 6.4B |
| Cost of Revenue | 5.3B | 2.4B | 2.9B | 2.8B | 3.0B |
| Gross Profit | 3.7B | 1.7B | 2.9B | 3.6B | 3.4B |
| Operating Expenses | |||||
| R&D Expense | 450.2M | 244.0M | 266.0M | 289.7M | 259.1M |
| SG&A Expense | 2.1B | 1.1B | 1.4B | 1.5B | 1.9B |
| General & Admin Expense | 499.3M | 340.4M | 299.2M | 91.0M | 284.8M |
| Selling & Marketing Expense | 1.1B | 736.2M | 1.1B | 1.4B | 1.7B |
| Other Expenses | (322.5M) | (213.4M) | (150.0M) | 161.3M | (60.3M) |
| Total Operating Expenses | 2.2B | 1.1B | 1.6B | 2.0B | 2.1B |
| Cost and Expenses | 7.4B | 3.5B | 4.4B | 4.8B | 5.0B |
| Operating Income (EBIT) | 1.5B | 628.9M | 1.3B | 1.6B | 1.4B |
| Non-Operating | |||||
| Interest Income | 26.3M | 21.1M | 29.5M | 33.9M | 29.2M |
| Interest Expense | 247.4M | 105.6M | 126.9M | 125.4M | 88.3M |
| Net Interest Income | (221.1M) | (84.5M) | (97.3M) | (91.5M) | (59.1M) |
| Other Non-Op Income/Expense | (103.5M) | (65.2M) | (61.9M) | (55.3M) | (24.6M) |
| Non-Operating Income (excl Interest) | (88.9M) | 33.4M | (311.0K) | (70.1M) | (63.7M) |
| EBT (Pre-Tax Income) | 1.4B | 563.7M | 1.3B | 1.6B | 1.4B |
| Income Tax Expense | 221.2M | 80.2M | 206.0M | 254.3M | 209.6M |
| Bottom Line | |||||
| Net Income | 1.2B | 470.6M | 1.1B | 1.3B | 1.1B |
| Earnings from Cont. Ops | 1.2B | 483.5M | 1.1B | 1.3B | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 470.6M | 1.1B | 1.3B | 1.1B |
| Per Share | |||||
| Basic EPS | HK$0.40 | HK$0.16 | HK$0.36 | HK$0.44 | HK$0.38 |
| Diluted EPS | HK$0.40 | HK$0.16 | HK$0.36 | HK$0.44 | HK$0.38 |
| Revenue Per Share | HK$3.10 | HK$1.42 | HK$1.95 | HK$2.18 | HK$2.16 |
| Shares | |||||
| Basic Shares Outstanding | 2.9B | 2.9B | 3.0B | 3.0B | 3.0B |
| Diluted Shares Outstanding | 2.9B | 2.9B | 3.0B | 3.0B | 3.0B |
| Profitability Metrics | |||||
| EBITDA | 2.3B | 1.0B | 1.7B | 2.1B | 1.9B |
| D&A | 838.6M | 439.8M | 394.9M | 405.6M | 371.1M |
| EBIT | 1.5B | 595.5M | 1.3B | 1.7B | 1.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026